Safety and efficacy of the complement inhibitor AMY-101 in a natural model of periodontitis in non-human primates

    • This study was undertaken to determine the local safety of increasing doses of the drug as well as its efficacy when given at a reduced frequency or after systemic administration.
    • A local dose of AMY-101 (0.1 mg/site) that is free of local irritation and effective when given once every 3 weeks was determined.
    • A daily subcutaneous dose of AMY-101 (4 mg/kg bodyweight) was protective against NHP periodontitis.
    • Conclusion: AMY-101 appears to be a promising candidate drug for the adjunctive treatment of human periodontitis.
Author and source information

Authors: Kajikawa T, Briones RA, Resuello RRG, Tuplano JV, Reis ES, Hajishengallis E, Garcia CAG, Yancopoulou D, Lambris JD, Hajishengallis G.
Reference: Mol Ther Methods Clin Dev. 2017 Aug 18;6:207-215. doi: 10.1016/j.omtm.2017.08.001. eCollection 2017 Sep 15.